Expect a Limited Role for the New HIV Drug, Juluca
February 2018
Juluca (jah-LOO-kah, dolutegravir/rilpivirine) will be the first two-drug combo that's a COMPLETE treatment regimen for HIV.
Most patients use THREE meds to treat HIV...often two nucleoSIDE/ nucleoTIDE reverse transcriptase inhibitors (NRTIs) PLUS another antiretroviral from a different class.
Juluca doesn't have an NRTI. It combines the integrase inhibitor, dolutegravir (Tivicay), with the NON-nucleoside reverse transcriptase inhibitor, rilpivirine (Edurant). It's a single tablet taken once daily.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote